Angiostatin is a naturally occurring protein found in several animal species, including humans. It is a endogenous angiogenesis inhibitor (i.e., it blocks the growth of new blood vessels), and it is currently underlying clinical trials for its use in anticancer therapy*.
Structure
Angiostatin is a 57 kDa fragment of a larger protein,
plasmin (itself a fragment of
plasminogen) enclosing three to five contiguous
Kringle modules. Each module contains two small
beta sheets and three
disulfide bonds.
Generation
Angiostatin is produced, for example, by
autoproteolytic cleavage of plasminogen, involving extracellular disulfide bond
reduction by
phosphoglycerate kinase. Furthermore angiostatin can be cleaved from plasminogen by different metalloproteinases (MMPs), elastase,
prostata-specific antigen (PSA), 13 KD serine protease, or 24KD endopeptidase.
Biological activity
Angiostatin is known to bind a lot of proteins, especially to
angiomotin and endothelial cell surface
ATP synthase but also
integrins,
annexin II,
C-met receptor,
NG2-proteoglycans,
tissue-type plasminogen activator,
chondroitin sulfate proteoglycans, and
CD26. Also smaller fragments of angiostatin has been shown to bind several other proteins. There is still considerable uncertainty on its mechanism of action, but it seems to involve for example inhibition of endothelial cell
migration,
proliferation and induction of
apoptosis.
Biochemistry | Oncology | Proteins